Abstract
A clinical trial of a Canadian preparation of antihemophilic factor has been completed. The mean percentage increase in the factor VIII coagulant activity in the plasma was determined to be 2.1 +/- 0.8 per unit per kilogram dose, which compares very favourably with published data. The mean half-life of antihemophilic factor was found to be 14.7 hours. Side effects and reactions to the product were minimal and the product has been rated as clinically effective. No significant differences between lots were noted in the in vivo response or the half-life.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Eyster M. E., Bowman H. S., Haverstick J. N. Adverse reactions to factor VIII infusions. Ann Intern Med. 1977 Aug;87(2):248–248. doi: 10.7326/0003-4819-87-2-248_1. [DOI] [PubMed] [Google Scholar]
- Hilgartner M. W., Sergis E. Current therapy for hemophiliacs: home care and therapeutic complications. Mt Sinai J Med. 1977 May-Jun;44(3):316–331. [PubMed] [Google Scholar]
- James H. L., Wickerhauser M. Development of large-scale fractionation methods. 3. Preparation of a factor VIII concentrate of intermediate-purity. Vox Sang. 1972;23(5):402–412. doi: 10.1111/j.1423-0410.1972.tb03827.x. [DOI] [PubMed] [Google Scholar]
- Johnson A. J., Karpatkin M. H., Newman J. [Clinical investigation of intermediate- and high-purity antihaemophilic factor (factor VIII) concentrates]. Br J Haematol. 1971 Jul;21(1):21–41. doi: 10.1111/j.1365-2141.1971.tb03414.x. [DOI] [PubMed] [Google Scholar]
- Newman J., Johnson A. J., Karpatkin M. H., Puszkin S. Methods for the production of clinically effective intermediate- and high-purity factor-VIII concentrates. Br J Haematol. 1971 Jul;21(1):1–20. doi: 10.1111/j.1365-2141.1971.tb03413.x. [DOI] [PubMed] [Google Scholar]
- Strauss H. S. Acquired circulating anticoagulants in hemophilia A. N Engl J Med. 1969 Oct 16;281(16):866–873. doi: 10.1056/NEJM196910162811603. [DOI] [PubMed] [Google Scholar]